WO2009070923A1

WO2009070923A1 - A pharmaceutical composition for treating melancholy and preparation method thereof

Info

Publication number: WO2009070923A1
Application number: PCT/CN2007/003399
Authority: WO
Inventors: Zuoguang Zhang
Original assignee: Chi, Yu-Fen
Priority date: 2007-11-30
Filing date: 2007-11-30
Publication date: 2009-06-11

Abstract

A pharmaceutical composition for treating melancholy and preparation method thereof, said pharmaceutical composition is prepared by using ginseng and jujube as raw materials.

Description

Medicine composition for treating depression and preparation method thereof

Technical field

The present invention relates to a pharmaceutical composition for treating depression caused by ginseng and jujube, which can be used as a medicine, a nutrient and a health food. The present invention also relates to a method of preparing the above pharmaceutical composition for treating depression. Background technique

Depression is a common disease. According to statistics, about 25% of women in the general population have experienced depression during their lifetime, and about 10% of men have experienced depression (Zhang Chunxing: Modern Psychology) . Data from the World Health Organization (WHO): The incidence of depression in the world is about 11%. There are currently about 340 million people with depression in the world, and this number is still on the rise. The survey found that in the next 20 years, depression It will rise to the second most common disease in the world.

In the prior art, the antidepressant drugs are mainly based on Prozac, Serote, Zoloft, etc. (SS-, SNRI, NDRI, etc. 5-HT, NE, DA reuptake inhibitors), and the mechanism of action is Increase the content of serotonin and other components in the human nervous medium to alleviate the symptoms of depression.

However, the anti-depressant drugs that have been asked have different degrees of side effects, such as increased suicide rate, headache, dizziness, dizziness, insomnia, lethargy, deafness, dry mouth, anorexia, increased appetite, weight gain, and increased blood pressure. , gastrointestinal discomfort, nausea, nausea, vomiting, indigestion, diarrhea, constipation, lower limb pain, skin rash, trembling, cramps, sweating, edema, loss of libido, sexual incompetence, etc. In recent years, anti-depressant drugs such as Prozac have become a serious concern in the society. The US Food and Drug Administration (FDA) in 2004 asked the pharmaceutical companies to relabel the main 32 anti-depressants on the market. Part of its side effects and warnings, and stressing to medical staff that these drugs may increase the chances of suicide in children and adolescents. Among them, Celite was found to have potential safety hazards as early as 1996, and has been recalled from the market since 2001. In June 2004, the US Attorney General of New York accused the British GlaxoSmithKline of concealing a study related to the use of Celet and "increasing the risk of suicidal tendencies and behavior among adolescents" in order to make a profit. In this context, how to develop a new generation of drugs with low side effects and significant anti-depressant effects has become a concern of the global pharmaceutical community. In recent years, scientists in the international medical community have made new breakthroughs in the study of the pathogenesis of depression. It has been found that in addition to the treatment of depression with 5-HT, E, and DA reuptake inhibition, adjustment can be adopted. The post-receptor mechanism of action is used to treat depression, and it has become a research and development hotspot for antidepressants in the pharmaceutical industry due to the advent of the post-receptor mechanism of action drug Rolipram. Rollipura is an inhibitor of phosphodiesterase 4 (PDE4). Clinical trials have shown that it has significant antidepressant effects, but it is forced to terminate R&D due to strong vomiting. Pula has developed a new generation of "receptor-poster mechanism anti-depression drugs" research and development ideas.

In summary, after understanding the limitations of the known technology, the applicant has carefully studied and explored, and in the spirit of perseverance, finally discovered the treatment of melancholy and jujube as the raw material for the treatment of depression. The pharmaceutical composition of the disease and the preparation method thereof, the following is a description of the cartridge of the present invention.

In order to overcome the deficiencies of the existing pharmaceutical preparations, the inventors have studied the pathogenesis and mechanism of action of traditional Chinese medicine for treating depression in combination with modern medical and pharmacological theories. On the basis of this, the inventors have proposed the present invention, and the object thereof is to provide A pharmaceutical composition or health food for treating depression caused by ginseng and jujube as raw materials. The pharmaceutical composition is characterized by a clear functional component and a mechanism of action, and the main functional component can be quantified, so that the quality is stable, the curative effect is obvious, the safety is high, and the administration is convenient.

Another object of the present invention is to provide a pharmaceutical composition for the treatment of depression or a method for preparing a health food prepared by using the above-mentioned ginseng and jujube as raw materials.

The solution of the medicament of the invention is the result of intensive research and exploration by the inventors, according to the pathology and pharmacology theory of modern medical treatment of depression, especially the anti-depression drug target research combined with the post-receptor mechanism, after a large number of animal experiments prove: Ginsenoside contains adenylate cyclase (AC) to stimulate adenosine and contains cAMP phosphodiesterase (CAPD) inhibitor; jujube cAMP can increase the expression of cAMP in human body, and the content of jujube is extremely small. (About 1 in 10,000) of jujube cAMP extracted and purified into jujube extract containing 1% jujube cAMP for anti-test depressive effect animal test results show that it has obvious anti-test depression function, and Jujube extract containing normal jujube cAMP does not have obvious anti-test depression function; ginsenoside, Jujube cAMP compatibility, synergistic effect, can further improve the utilization and activity of cAMP, and the concentration and activity of cAMP can increase the synthesis and release of neurotransmitters such as norepinephrine (E). The expression of brain-derived neurotrophic factor (BDNF) inhibits the hyperthalamic-pituitary-adrenal axis (HPA axis) and the secretion of glucocorticoids, thereby achieving significant Anti-depressant function. Ginseng and jujube are commonly used medicines and foods for traditional Chinese medicine and food supplement diets for thousands of years. In the course of food and clinical use for thousands of years, the safety of ginseng and jujube has been fully proved, and ginseng and large ginseng are used. Jujube does not cause side effects such as strong vomiting. Therefore, the inventors propose to use ginseng and jujube as raw materials to prepare oral or health foods for the treatment of depression. In particular, the efficacy ingredients are clear, and long-term safety is high, and will not cause New technical solutions for side effects such as strong vomiting to improve the deficiencies in the known art.

In order to accomplish the object of the present invention, the following technical solutions are proposed.

The present invention discloses a pharmaceutical composition for treating depression, which is made from a raw material including ginseng and jujube.

Preferably, the pharmaceutical composition of the present invention is prepared from a raw material comprising 4 to 62 parts by weight of ginseng and 2 to 42 parts by weight of jujube.

Preferably, the pharmaceutical composition of the present invention is prepared from a raw material comprising 10 to 30 parts by weight of ginseng and 4 to 20 parts by weight of jujube.

According to another concept of the present invention, the present invention discloses a pharmaceutical composition for treating depression, which is prepared from a raw material including ginseng and jujube extract extract.

Preferably, the pharmaceutical composition of the present invention comprises an extract of ginseng comprising 4 to 62 parts by weight of ginsenosides (Rgl + Rbl ) and an extract of jujube extract containing 0.01-0.2 parts by weight of jujube cyclic adenosine monophosphate. Made of raw materials.

Preferably, the pharmaceutical composition of the present invention is a raw material comprising a ginseng extract containing 12-36 parts by weight of ginsenosides (Rgl + Rbl ) and a jujube extract containing 0.024-0.12 parts by weight of jujube cyclic adenosine monophosphate. Made.

Preferably, the jujube extract used in the pharmaceutical composition of the present invention is the following second extract: first extracting the jujube to obtain the extract, and then purifying the first extract to obtain the second extract; The concentration of the cyclic adenosine monophosphate (jujube cAMP) of the second extract in the second extract is higher than the concentration of the cyclic adenosine monophosphate of the first extract.

According to another concept of the present invention, the present invention discloses a method of preparing a pharmaceutical composition for treating depression, comprising the steps of:

(a) 4 to 62 parts by weight of ginseng is crushed and then extracted with an ethanol solution or water to obtain a first extract, and the first extract is separated and purified by column chromatography to obtain a second extract, wherein the second extract is obtained. The concentration of ginsenoside (Rgl + Rbl ) of the second extract is higher than the concentration of ginsenoside (Rgl + Rbl ) of the first extract;

(b) 2~42 parts by weight of the jujube is broken and then extracted with water to obtain a first extract, and the first extract is separated and purified by column chromatography to obtain a second extract, wherein the second extract is obtained. The concentration of the adenosine monophosphate of the jujube is higher than the concentration of the adenosine monophosphate of the first extract;

(c) The ginseng second extract obtained in the steps (a) and (b) and the jujube second extract are mixed and pulverized to obtain the pharmaceutical composition of the present invention.

Preferably, the pharmaceutical composition of the present invention can be processed into a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a microclay, a suspension, an emulsion, a granule, and a drip. One of the oral pharmaceutical dosage forms of pills, pills and pharmaceutics.

Preferably, the pharmaceutical compositions of the invention may comprise a pharmaceutically acceptable carrier or additive. Preferably, the pharmaceutical compositions of the invention are also useful in the manufacture of health foods and nutraceuticals.

The above pharmaceutical composition is a core formulation for achieving the object of the present invention, and after the present invention is disclosed, those skilled in the art can routinely add and subtract the above-mentioned pharmaceutical composition according to the theory of traditional Chinese medicine or related modern pharmacological theory. Such conventional addition and subtraction is a general technical activity of those skilled in the art, and any general technical additions and subtractions made on the basis of the formulation of the pharmaceutical composition of the present invention are within the scope of the present invention.

The invention may be better understood by reference to the drawings and accompanying drawings. BRIEF abstract

BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a schematic view showing the flow of a method for preparing a medicament of Example 1 of the present invention.

2 is a schematic flow chart of a method for preparing a medicament of Example 2 of the present invention. Preferred embodiment of the invention

The invention will be further illustrated by the following figures and examples. The present invention is primarily directed to the preparation of the medicaments of the present invention in combination with the features of the present invention using methods well known to those skilled in the art. The following examples are for illustrative purposes only and are not intended to limit the invention.

In order to accomplish the object of the present invention, the present invention particularly proposes the following technical solutions.

Option One:

The pharmaceutical composition for treating depression of the present invention is prepared from a raw material including ginseng and jujube.

Option II:

The pharmaceutical composition for treating depression of the present invention is prepared from a raw material comprising 4 to 62 parts by weight of ginseng and 2 to 42 parts by weight of jujube.

third solution:

The pharmaceutical composition for treating depression of the present invention is prepared from a raw material comprising 10 to 30 parts by weight of ginseng and 4 to 20 parts by weight of jujube.

Option 4:

The pharmaceutical composition for treating depression of the present invention is prepared from a raw material comprising ginseng extract and jujube extract.

Option 5:

The medicament for treating depression of the present invention is prepared from a raw material comprising a ginseng extract containing 4-62 parts by weight of ginsenosides (Rgl + Rbl ) and a jujube extract containing 0.01-0.2 parts by weight of jujube cyclic adenosine monophosphate. combination. Option six:

The pharmaceutical composition for treating depression is prepared from a raw material comprising a ginseng extract containing 12 36 parts by weight of ginsenosides (Rgl + Rbl ) and a jujube extract containing 0.024-0.12 parts by weight of jujube cyclic adenosine monophosphate. Things.

Option seven:

The jujube extract according to the fourth aspect of the present invention is the second extract: first extracting jujube to obtain a first extract, and then purifying the first extract to obtain a second extract; wherein the second extract The concentration of the adenosine adenosine monophosphate of the substance is higher than the concentration of the adenosine adenosine monophosphate of the first extract.

Option eight:

The pharmaceutical composition of the invention for treating depression is prepared by a preparation method comprising the following steps:

(a) After crushing 4-62 parts by weight of ginseng, the first extract is obtained by heating with ethanol solution or water, and the first extract is separated and purified by column chromatography to obtain a second extract, wherein The concentration of ginsenoside (Rgl + Rbl ) of the second extract is higher than the concentration of ginsenoside (Rgl + Rbl ) of the first extract

(b) after crushing 2 to 42 parts by weight of jujube, extracting the extract with water and heating, and separating and purifying the extract of the same extract by column chromatography to obtain a second extract, wherein The concentration of the adenine cyclic adenosine monophosphate of the second extract is higher than the concentration of the adenosine adenosine monophosphate of the first extract;

Option nine:

The pharmaceutical composition of the present invention can be processed into a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-dip, a suspension, an emulsion, a granule, a pill, and a pill. And one of the pharmacy oral pharmaceutical dosage forms. Option 10:

The pharmaceutical compositions of the invention may include a pharmaceutically acceptable carrier or additive.

Option 11:

The pharmaceutical compositions of the invention may also be used to formulate health foods and nutrients.

In order to accomplish the object of the present invention, the following pharmaceutical preparation methods are specifically proposed.

method one:

Raw materials including ginseng and jujube are processed into a pharmaceutical composition for treating depression in the present invention.

Method Two:

A raw material comprising 4 to 62 parts by weight of ginseng and 2 to 42 parts by weight of jujube is processed to prepare a pharmaceutical composition for treating depression in the present invention.

Method three:

A raw material comprising 10 30 parts by weight of ginseng and 4-20 parts by weight of jujube is processed to prepare a pharmaceutical composition for treating depression in the present invention.

Method four:

A raw material including ginseng extract and jujube extract is processed to prepare a pharmaceutical composition for treating depression in the present invention.

Method five:

Will include 4-62 parts by weight of ginsenosides (Rgl + Rbl) and contain 0.01-0.2 The raw material of the jujube extract of the jujube cyclic adenosine monophosphate is processed to prepare a pharmaceutical composition for treating depression in the present invention.

Method six:

It will include ginseng extract containing 12~36 parts by weight of ginsenosides (Rgl + Rbl ) and

The raw material of the jujube extract of 0.024-0.12 parts by weight of jujube cyclic adenosine monophosphate is processed to prepare a pharmaceutical composition for treating depression in the present invention.

Method seven:

The jujube extract according to the fourth method is the following second extract: first extracting jujube to obtain a first extract, and then purifying the first extract to obtain a second extract; wherein the second extract is The concentration of cyclic adenosine monophosphate in jujube is higher than the concentration of adenosine monophosphate in the first extract.

Method eight:

(a) 4 to 62 parts by weight of ginseng is crushed and then extracted with an ethanol solution or water to obtain a first extract, and the first extract is subjected to column chromatography separation and purification to obtain a second extract, wherein The concentration of ginsenoside (Rgl + Rbl ) of the second extract is higher than the concentration of ginsenoside (Rgl + Rbl ) of the first extract;

(b) 22-4 parts by weight of jujube is broken and then extracted with water to obtain a first extract, and the first extract is separated and purified by column chromatography to obtain a second extract, wherein the second extract The concentration of the adenosine monophosphate of the jujube is higher than the concentration of the adenosine monophosphate of the first extract;

Method nine: The pharmaceutical composition of the present invention is processed into a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, an elixir, a suspension, an emulsion, a granule, a pill, and a pill. And one of the pharmacy oral pharmaceutical dosage forms.

Method ten:

The pharmaceutical compositions of the invention are processed to include a pharmaceutically acceptable carrier or additive.

Method 11:

The pharmaceutical composition of the present invention is processed into a health food and a nutrient.

Specific embodiment

The invention will be further illustrated by the following figures and specific examples.

Example 1

Please refer to FIG. 1, which is a schematic flow chart of a method for preparing the drug of the embodiment 1 of the present invention. In Fig. 1, 10 kg of ginseng was crushed, and the ginseng extract was extracted with 70% ethanol solution, and the ginseng extract was separated and purified by column chromatography, and dried to obtain 0.4 kg of ginseng extract (including 60). g ginsenoside Rgl + Rbl ); 2 kg jujube is crushed, soaked in water at room temperature, and extracted with water and alcohol precipitation to obtain jujube extract, and then the extract is made of macroporous resin OU-2, ME-2 The column was successively adsorbed and separated by a column, and dried to obtain 6 g of jujube extract (containing 0.06 g of jujube cAMP). The extract obtained in the above step was mixed and pulverized uniformly to obtain 406 g of the pharmaceutical composition of the present invention.

Example 2

Please refer to FIG. 2 , which is a schematic flow chart of a method for preparing the drug of Example 2 of the present invention. In Fig. 2, 1.2 g of ginsenoside Rgl having a purity of 90% and 2.8 g of ginsenoside Rbl having a purity of 90% are directly mixed with 0.8 g of a large amount of 0.8 mg of jujube cAMP. Uniform, that is, 4.8 g of the drug extract composition of the present invention. Experimental Example 1 Effect of Example 1 on Mouse Suspension Experiment

1.1 Real animal

' ICR mice, male, weighing 22.0 ± 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.

1.2 Experimental drugs

Example 1: Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.

Paroxetine (Selite): Sino-US Tianjin Shike Pharmaceutical Co., Ltd. products.

1.3 Experimental instruments

Stopwatch.

1.4 Dose design

Example 1 High dose of 60 mg/kg/d, medium dose of 30 mg/kg/d and low dose of 15 mg/kg/d

1.5 Experimental methods and results

1.5.1 Group administration

Mice were randomized into groups of 10: 1. Example 1 high dose group (60 mg/kg, PO, 7d administration); 2. Example 1 dose group (30 mg/kg, PO, administration) 7d); 3. Example 1 low dose group (15 mg / kg, PO, 7d); 4. Paroxetine group (3 mg / kg, PO, 7d); 5. Saline group (PO) . A tail suspension experiment was performed 1 hour after the last administration.

1.5.2 Experimental method

The tail of the mouse (1 cm from the tip of the tail) was glued to the wooden strip with a head height of 5 cm.

6 minutes, the immobility time of the mice within 5 minutes after recording.

1.5.3 Statistical processing

The experimental data were expressed by ±SD, and the experimental results were analyzed by SPSS 11.5 statistical software for analysis of variance. 1.5.4 Experimental results

See Table 1 for the experimental results.

Table 1. Effect of Example 1 on immobility time in mice Number of animals in the group (only) Immobility time (seconds) Physiological benefit water group (model group) 10 122.18±45.78 Paroxetine group 10 67.59±32.09** Example 1 High dose group 10 106.92±36.89 Example 1 medium dose group 10 59.57±37.63** Example 1 Low dose group 10 82.83±29.40* Note: Compared with the model group * P<0.05 **P<0.01

in conclusion:

According to the above experiment, it can be seen that the high, medium and low dose groups and the paroxetine group of the present invention can reduce the immobility time of the mice after the tail suspension, the middle dose and the low dose group and the saline group (model group). Compared with the significant difference, it can be inferred that the first embodiment of the present invention has anti-experimental depression work.

At,

Experimental Example 2 Example 1 Effect on forced swimming test in mice

2.1 Real animals

ICR mice, male, weighing 22.0±2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.

2.2 Real drugs

Example 1: Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.

Paroxetine (Selite): Sino-US Tianjin Shike Pharmaceutical Co., Ltd. products.

2.3 Experimental instruments

Stopwatch.

2.4 dose design

Example 1 High dose is 60 mg/kg/d, medium dose is 30 mg/kg d and low dose is I ⁵

2.5. Experimental methods and results 2.5.1 Group administration

Mice were randomized into groups of 10: 1. Example 1 high dose group (60 mg/kg, PO, 7d administration); 2. Example 1 dose group (30 mg/kg, PO, administration) 7d); 3. Example 1 low dose group (15 mg / kg, PO, 7d administration); 4. Paroxetine group (3 mg kg, PO, 7d administration); 5. Saline group (PO). A forced swimming test was performed 1 hour after the last administration.

2.5.2 Experimental methods

The mice were placed in a glass jar with a water depth of 10 cm and a diameter of 14 cm, and the water temperature was 25 ° C. The cumulative immobility time of the mice in the water was recorded for 5 minutes.

2.5.3 Statistical processing

The experimental data was expressed in soil, and the experimental results were analyzed by SPSS 11.5 statistical software for analysis of variance. 2.5.4 Experimental results

See Table 2 for the experimental results.

Table 2. Example 1 Effect on immobility time of mice

Group Number of animals (only) Immobility time (seconds) Saline group (model group) 10 114.83±40.59 Paroxetine group 10

76.58±45.04*

Example 1 High dose group 10 73.27±42.30* Example 1 Medium dosage group 10

64.33±35.82**

Example 1 Low dose group 10 88.96±38.76 Note: Compared with the model group * P<0.05 *叩<0.01

in conclusion:

According to the above, it can be seen that the high, medium and low dose groups and the paroxetine group of the present invention can significantly shorten the cumulative immobility time of the forced swimming in the mice, the middle dose group and the high dose group and the saline group (model) There is a significant difference compared to the group), so it can be inferred that the embodiment 1 of the present invention has anti-reality Depressive depression.

The scope of application of the oral medicament of the present invention for treating depression:

1. The oral drug for treating depression according to the present invention may contain a pharmaceutically acceptable additive;

2. The oral medicament for treating depression according to the present invention can be processed into various known dosage forms such as powders, capsules, tablets, and the like;

3. The oral medicament for treating depression according to the present invention can be formulated into a health food for treating depression.

A person skilled in the art can make various modifications to the invention without departing from the scope of the appended claims.

Claims

Claim

A pharmaceutical composition for treating depression, which is prepared from a raw material comprising ginseng and jujube.

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is further prepared from a raw material comprising 4 to 62 parts by weight of ginseng and 2 to 42 parts by weight of jujube.

The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition is further prepared from a raw material comprising 10 to 30 parts by weight of ginseng and 4 to 20 parts by weight of jujube.

4. The pharmaceutical composition according to claim 1, wherein the medicament comprises a carrier selected from the group consisting of pharmaceutically acceptable carriers, additives, and combinations thereof.

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is in a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-tank, and a suspension. One of the oral pharmaceutical dosage forms of the agent, emulsion, granule, pill, pill and pharmacy.

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated into a health food or a nutrient.

A pharmaceutical composition for treating depression, which is prepared from a raw material comprising ginseng extract and jujube extract.

The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition comprises the ginseng extract containing 4 to 62 parts by weight of ginsenoside (Rgl + bl ) and 0.01 to 0.2 parts by weight of jujube cyclophosphate The jujube extract of adenosine.

The pharmaceutical composition according to claim 8, wherein the pharmaceutical composition further comprises the ginseng extract containing 12 to 36 parts by weight of ginsenoside (Rgl + Rbl ) and 0.04-10.12 parts by weight of jujube ring Jujube extract of adenosine phosphate.

The pharmaceutical composition according to claim 7, wherein the raw material containing jujube cyclic adenosine monophosphate is the following second extract: first extracting jujube to obtain a first extract, and then purifying the first extract The extract obtains the second extract, wherein the concentration of the jujube cyclic adenosine monophosphate of the second extract is higher than the concentration of the jujube succinate adenosine of the first extract.

The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition contains a drug selected from the group consisting of Acceptable carriers, additives, and combinations thereof.

The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is in a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-tank, and a mixture. Suspension, emulsion, granules, pills, pills, and one of the pharmaceutically acceptable oral dosage forms.

13. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is formulated into a health food and a nutrient.

14. A method of preparing a pharmaceutical composition for treating depression comprising the steps of:

(a) extracting 4 to 62 parts by weight of ginseng to obtain a first ginseng extract;

(b) extracting 2 to 42 parts by weight of jujube to obtain the first jujube extract;

(c) purifying the first jujube extract to obtain a second jujube extract;

(d) mixing the first ginseng extract and the second jujube extract to obtain the pharmaceutical composition, wherein the second jujube extract has a higher concentration of cyclic adenosine monophosphate than the first Jujube extract adenosine monophosphate concentration in jujube extract.

The preparation method according to claim 14, wherein the step (a) further comprises:

(al) purifying the first ginseng extract to obtain a second ginseng extract,

Wherein the concentration of ginsenoside (Rgl + Rbl ) of the second ginseng extract is higher than the concentration of ginsenoside (Rgl + RM ) of the first ginseng extract.

The preparation method according to claim 14, wherein the step (c) adsorbs and separates the jujube cyclic adenosine monophosphate in the first jujube extract by using a matrix-containing macroporous resin column.

The preparation method according to claim 16, wherein the step (c) is carried out by using a macroporous resin OU-2 containing a waking group to adsorb and separate the jujube cyclic adenosine monophosphate in the extract of the jujube.

The preparation method according to claim 14, wherein the step (c) further separates the jujube cyclic adenosine monophosphate in the first jujube extract with a macroporous resin ME-2 column.